Oxytocin receptor blockade and prostaglandin release in late pregnant sheep.
The oxytocin receptor inhibitor 1-deamino-2-D-Tyr-(oET)-4-Thr-8-orn-oxytocin (CAP) was infused into late pregnant sheep. Basal and oxytocin-induced prostaglandin (PG) concentrations in maternal and fetal plasma were determined. CAP had no significant effect on maternal PGFM or PGE2 or fetal PGF2 alpha, PGFM or PGE2 concentrations during late pregnancy or at term. PGF2 alpha was not detectable in maternal peripheral plasma. CAP infusion did not affect fetal well-being. Oxytocin injection to the mother caused a significant, dose-dependent, increase in maternal plasma PGFM concentrations but did not alter maternal PGE2 concentrations or fetal PGF2 alpha and PGE2 concentrations. The increase in maternal PGFM concentrations brought about by oxytocin injection was decreased during intrauterine infusion of CAP over the range of 12.5-100 micrograms/min. A rationale for the use of oxytocin receptor blockade for the prevention of premature labor is thus provided.
Jenkin
G
G
Department of Physiology, Monash University, Clayton Victoria, Australia.
Buttress
D
D
Harding
R
R
D000818:Animals; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D015232:Dinoprostone / Q000097:blood; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D010121:Oxytocin / Q000494:pharmacology; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism*; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors*; D012756:Sheep; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
D011453:Prostaglandins; D018045:Receptors, Oxytocin; C047046:atosiban; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D010121:Oxytocin; D015237:Dinoprost; D015232:Dinoprostone; D014668:Vasotocin